SKYE

Skye Bioscience Inc

Add to Watchlist

Advanced Chart

1.940

-0.110(-5.370%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

2.040

Open

2.000

VWAP

1.96

Vol

191.39K

Mkt Cap

60.11M

Low

1.910

Amount

374.98K

EV/EBITDA(TTM)

Total Shares

30.98M

1.23M

EV/OCF(TTM)

P/S(TTM)

Skye Bioscience, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system. The Company's clinical assets focus on the modulation of cannabinoid receptor 1 (CB1) to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. Its Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion (SBI-100 OE), a CB1 agonist (activator), being developed for the treatment of glaucoma and ocular hypertension. The Company's Phase 2 study in obesity is designed to evaluate nimacimab's weight loss potential either as a single agent or in combination with a glucagon-like peptide-1 (GLP-1) agonist like semaglutide.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

-0.287

-1.27%

-0.305

+198.14%

-0.300

+50%

Estimates Revision

The market is revising No Change the revenue expectations for Skye Bioscience, Inc. (SKYE) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -38.61%.

EPS Estimates for FY2025

Revise Upward

+1.01%

In Past 3 Month

Stock Price

Go Down

-38.61%

In Past 3 Month

0 Analyst Rating

Wall Street analysts forecast SKYE stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SKYE is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

0 Hold

0 Sell

Current: 1.940

Low

Averages

High

Current: 1.940

Low

Averages

High

Citizens Capital Markets

Jonathan Wolleben

Buy

Reiterates

$15

2025-03-21

Reason

Citizens Capital Markets

Jonathan Wolleben

Price Target

$15

2025-03-21

Reiterates

Buy

Reason

Craig-Hallum

Albert Lowe

Strong Buy

Maintains

$18 → $14

2025-03-21

Reason

Craig-Hallum

Albert Lowe

Price Target

$18 → $14

2025-03-21

Maintains

Strong Buy

Reason

Craig-Hallum analyst Albert Lowe lowered the firm's price target on Skye Bioscience to $14 from $18 and keeps a Buy rating on the shares. The firm notes that due to enrollment of the ongoing Phase II study of nimacimab in obesity completing ahead of schedule, the company is removing the previously planned Q2 2025 interim analysis in favor of moving up the topline readout to September/October, from Q4 2025 previously. While this change makes the first look at the obesity data slightly later, the topline dataset for this important catalyst will be more robust, containing 26-week data on all 136 patients, Craig-Hallum adds. The benchmark for success will be an 8% weight loss with Albert focused on improvements in GI tolerability and lean mass preservation relative to GLP1 therapies. In addition, an open-label extension was added to increase the treatment time to 52 weeks, giving nimacimab sufficient time to show its full weight loss potential in future updates.

William Blair

Andy Hsieh

Buy

Initiates

n/a

2025-02-28

Reason

William Blair

Andy Hsieh

Price Target

n/a

2025-02-28

Initiates

Buy

Reason

Scotiabank

George Farmer

Buy

Initiates

$20

2024-09-30

Reason

Scotiabank

George Farmer

Price Target

$20

2024-09-30

Initiates

Buy

Reason

Cantor Fitzgerald

Kristen Kluska

Buy

Reiterates

$14

2024-09-20

Reason

Cantor Fitzgerald

Kristen Kluska

Price Target

$14

2024-09-20

Reiterates

Buy

Reason

Piper Sandler

Edward Tenthoff

Buy

Reiterates

$20

2024-09-20

Reason

Piper Sandler

Edward Tenthoff

Price Target

$20

2024-09-20

Reiterates

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Skye Bioscience Inc (SKYE.O) is -1.64, compared to its 5-year average forward P/E of -2.07. For a more detailed relative valuation and DCF analysis to assess Skye Bioscience Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.07

Current PE

-1.64

Overvalued PE

1.56

Undervalued PE

-5.70

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00